1Colditz GA,Hankinson SE,Hunter DJ,et al.The use of estrogens and progestins and the risk of breast cancer in postmenopausal women[J].N Engl J Med,1995,332 (24):1589-1593.
3Gaub MP,Bellard M,Scheuer I,et al.Activation of the ovalbumin gene by estrogen receptor involves the fos-jun complex[J].Cell,1990,63(6):1267-1276.
4Paech K,Webb P,Kuiper GG,et al.Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites[J].Science,1997,277(5331):1508-1510.
5Di Nunno L,Lareson L G,Rinehart JJ,et al.Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical reseetion[J].Arch Pat hol Lab Med,2000,124 (10):1467-1470.
6Mollerup S,Jorgensen K,Berge G,et al.Expression of estrogen receptors alpha and beta in human lung tissue and cell lines[J].Lung Cancer,2002,37 (2):153-159.
3Rapp EA, Pater JL, William A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer Report of a canadian multicenter randomized trial [J]. J Clin Oncol, 1998;6(3):633 - 641
4Monoz M, Rosell R, Sanche Z, et al. Paclitacel resistance in nonsmall-cell lung cancer associated with beta-tubulin gene mutations [J].J Clin Oncol, 1999; 17(6): 1786 - 1793
5Song S, Wientjes MG, Walsh C, et al. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases [J]. Cancer Res,2001 ;61(16) :6145 - 6150
6Oguri T, Isobe T, Fujitaka K. Association between expression of the MRP3 gene and exposure to platinum durgs in lung cancer [J]. Int J Cancer, 2001 ;93(4) :548 - 549
7Oguri T, Fujiwara Y, Ochiai M, et al. Expression of lung-resistance protein is not associated with platinum drug exposure in lung cancer [J]. Anticancer Res, 1999;18:4159-4162
8American Society of Clinical Oncology (ASCO). Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol, 1997; 15(9) :2996 - 3018
9Finkelstein DM, Ettinger DS, Ruckdeschel JC. long-term survivors in metastatic non-small-cell lung cancer: An Fastem Cppoerative Group Study. J C lin Oncol, 1986;4(5) :702 - 709
10Ray-Coquard I, Biron P, Bachelot T, et al. Vinorelbine and cisplatin (CIVIC regimen) for the or paclitaxel-containing regimens. Cancer,1998;82(1): 134 - 140
6Noble J. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: A systematic review and practice guideline[ J]. J Thorac Oncol, 2006,1 : 1042-1058.
7Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer [J]. N Engl J Med, 2002, 346:92-98.
8Donnenberg VS, Donnenberg AD. Multidrug resistance in cancer revisited: the cancer stem cell hypothesis[ J]. J Clin Pharmacol, 2005,45 ( 8 ) :872-877.
9Liippo K, Ellmen J, Vanttinen E, et al. Toremifene concentration and multidrug resistance in lung tumors [ J ]. Cancer Chemother Pharmacol, 1997,39:212-216.
10Lara PJr, Gandara DR, Longmate J, et al. Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase 11 California Cancer Consortium Trial [ J ]. Cancer Chemother Pharmaco1,2001,48 ( 1 ) :22-28.
